Effect of Alpha-Blockers on Patients with Benign Prostatic Hyperplasia with Inflammatory Cells in the Prostatic Fluid

Yu-Mi Seo; Hyung-Jee Kim

doi:10.14777/uti.2018.13.02.40

Journal List > Urogenit Tract Infect > v.13(2) > 1100741

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Seo and Kim: Effect of Alpha-Blockers on Patients with Benign Prostatic Hyperplasia with Inflammatory Cells in the Prostatic Fluid

Original Article

Urogenit Tract Infect 2018;13(2):40-44.

Published online: 19 August 2018

DOI: https://doi.org/10.14777/uti.2018.13.02.40

Effect of Alpha-Blockers on Patients with Benign Prostatic Hyperplasia with Inflammatory Cells in the Prostatic Fluid

Yu-Mi Seo, Hyung-Jee Kim

Department of Urology, Dankook University College of Medicine, Cheonan, Korea

Correspondence to: Hyung-Jee Kim http://orcid.org/0000-0002-7993-1881 Department of Urology, Dankook University Hospital, 201 Manghyang-ro, Dongnam-gu, Cheonan 31116, Korea Tel: +82-41-550-6630, Fax: +82-41-556-7060 E-mail: killtumor@dankook.ac.kr

Received 30 April 2018 Revised 27 June 2018 Accepted 4 August 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose:

To determine if alpha-blocker monotherapy is effective on patients with benign prostatic hyperplasia (BPH) and prostatic inflammation.

Materials and Methods:

Patients who were admitted for the treatment of lower urinary tract symptoms for 18 months were enrolled in this study. All were subjected to an International Prostate Symptom Score (IPSS) evaluation, prostate specific antigen analysis, urinalysis, residual urine testing, prostate massage, and transrectal prostate ultrasonography. The presence of inflammation in the secretion after the prostate massage was observed at high magnification. Patients with a leukocyte count of more than 15 were diagnosed as positive and classified as group 1 (experimental group), whereas those with a leukocyte count of less than 15 were diagnosed as negative and classified as group 2 (control group). Silodosin was administered (4 mg twice a day for two months).

Results:

Group 1: After one and two months, there was no significant difference in the maximum urinary flow rate (Qmax) and post-void residual volume (PVR) compared to the baseline. The total IPSS was significantly improved over the 8-week study period. All symptoms except for Qmax and PVR showed significant improvement in the second month. Group 2: After one and two months, significant improvement was observed in all domains of the IPSS, and Qmax and PVR assessment, except for the PVR at one month.

Conclusions:

In patients with BPH who have not been treated properly, other treatments based on prostatitis may be needed in addition to alpha blockers if there is inflammation on expressed secretion of prostate.

Keywords: Prostate, Inflammation, Adrenergic alpha-antagonists

REFERENCES

1.Chute CG., Panser LA., Girman CJ., Oesterling JE., Guess HA., Jacobsen SJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993. 150:85–9.

2.Kim TH., Han DH., Ryu DS., Lee KS. The impact of lower urinary tract symptoms on quality of life, work productivity, depressive symptoms, and sexuality in Korean men aged 40 years and older: a population-based survey. Int Neurourol J. 2015. 19:120–9.

3.Malaeb BS., Yu X., McBean AM., Elliott SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). Urology. 2012. 79:1111–6.

4.Collins MM., Stafford RS., O'Leary MP., Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol. 1998. 159:1224–8.

5.Roberts RO., Lieber MM., Rhodes T., Girman CJ., Bostwick DG., Jacobsen SJ. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology. 1998. 51:578–84.

6.Cho IR. Evaluation and treatment of patients with prostatitis. Korean J Androl. 2005. 23:1–11.

7.Woo YN. Prostatitis. Korean J Urol. 1994. 35:575–85.

8.Nickel JC. The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. Curr Opin Urol. 2006. 16:5–10.

9.Nickel JC., Downey J., Young I., Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999. 84:976–81.

10.Kohnen PW., Drach GW. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol. 1979. 121:755–60.

11.Collins MM., Meigs JB., Barry MJ., Walker Corkery E., Giovannucci E., Kawachi I. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol. 2002. 167:1363–6.

12.Daniels NA., Ewing SK., Zmuda JM., Wilt TJ., Bauer DC. Correlates and prevalence of prostatitis in a large community-based cohort of older men. Urology. 2005. 66:964–70.

13.Nickel JC., Elhilali M., Vallancien G. ALF-ONE Study Group. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. BJU Int. 2005. 95:571–4.

14.Schaeffer AJ., Landis JR., Knauss JS., Propert KJ., Alexander RB., Litwin MS, et al. Demographic and clinical characteristics of men with chronic prostatitis: the national institutes of health chronic prostatitis cohort study. J Urol. 2002. 168:593–8.

15.McNaughton Collins M., MacDonald R., Wilt TJ. Diagnosis and treatment of chronic abacterial prostatitis: a systematic review. Ann Intern Med. 2000. 133:367–81.

16.Ryu YG., Kim HJ., Park HJ. The efficacy of alfuzosin for chronic prostatitis/chronic pelvic pain syndrome in young and middle aged patients. Korean J Urol. 2007. 48:858–62.

17.Nickel JC. Alpha-blockers for treatment of the prostatitis syndromes. Rev Urol. 2005. 7(Suppl 8):S18–25.

18.Chapple CR., Montorsi F., Tammela TL., Wirth M., Koldewijn E., Fernandez Fernandez E. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011. 59:342–52.

19.Nickel JC., O'Leary MP., Lepor H., Caramelli KE., Thomas H., Hill LA, et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study. J Urol. 2011. 186:125–31.

Table 1.

Changes in the International Prostate Symptom Score (IPSS) of all patients

	Baseline	First month	Second month	p-value^a)	p-value^b)	p-value^c)
IPSS, total	20.1±6.7	16.7±7.6	13.1±6.9	0.034	0.001	0.001
IPSS, voiding symptom	12.7±4.7	9.8±5.0	7.2±4.5	0.033	0.001	0.001
IPSS, storage symptom	8.0±3.3	6.9±3.4	5.7±3.2	0.047	0.001	0.002
IPSS, quality of life	4.5±1.1	3.9±1.3	3.2±1.2	0.005	0.001	0.001
Qmax (ml/sec)	10.8±4.1	12.5±6.3	13.0±4.8
PVR (ml)	55.5±51.2	48.1±44.8	44.2±33.0

Values are presented as mean±standard deviation.

Qmax: maximum urinary flow rate, PVR: post-void residual volume.

^a) p-value compared baseline to the first month.

^b) p-value compared baseline to the second month.

^c) p-value compared first month to the second month.

Table 2.

Changes in the International Prostate Symptom Score (IPSS) of the experimental group (group 1)

	Baseline	First month	Second month	p-value^a)	p-value^b)	p-value^c)
IPSS, total	20.7±7.6	17.9±7.5	14.6±7.0	0.228	0.001	0.011
IPSS, voiding symptom	12.2±5.1	10.2±4.7	7.9±4.5	0.05	0.001	0.027
IPSS, storage symptom	8.3±3.5	7.7±3.5	6.3±3.4	0.258	0.011	0.011
IPSS, quality of life	4.6±1.1	4.3±1.2	3.6±1.1	0.367	0.001	0.024
Qmax (ml/sec)	10.6±2.6	12.3±5.6	12.1±4.5
PVR (ml)	41.3±44.1	41.5±36.4	46.8±31.8

Values are presented as mean±standard deviation.

Qmax: maximum urinary flow rate, PVR: post-void residual volume.

^a) p-value compared baseline to the first month.

^b) p-value compared baseline to the second month.

^c) p-value compared first month to the second month.

Table 3.

Changes in the International Prostate Symptom Score (IPSS) of the control group (group 2)

	Baseline	First month	Second month	p-value^a)	p-value^b)	p-value^c)
IPSS, total	19.3±5.4	15.2±7.7	10.6±6.2	0.009	0.001	0.004
IPSS, voiding symptom	11.7±4.3	9.3±5.3	5.9±4.3	0.006	0.001	0.003
IPSS, storage symptom	7.6±3.2	5.9±3.0	4.7±2.5	0.039	0.002	0.025
IPSS, quality of life	4.3±1.1	3.4±1.3	2.6±1.0	0.002	0.002	0.006
Qmax (ml/sec)	11.1±5.5	14.4±7.0	14.3±5.1
PVR (ml)	63.6±55.1	56.1±53.4	40.1±35.6

Values are presented as mean±standard deviation.

Qmax: maximum urinary flow rate, PVR: post-void residual volume.

^a) p-value compared baseline to the first month.

^b) p-value compared baseline to the second month.

^c) p-value compared first month to the second month.

TOOLS

Similar articles